跳到主要导航 跳到搜索 跳到主要内容

Pharmacological and Biological Targeting of FGFR1 in Cancer

  • Shuai Fan
  • , Yuxin Chen
  • , Wenyu Wang
  • , Wanting Xu
  • , Mei Tian
  • , Yuetong Liu
  • , Yutong Zhou
  • , Dan Liu
  • , Qin Xia*
  • , Lei Dong*
  • *此作品的通讯作者
  • Beijing Institute of Technology

科研成果: 期刊稿件 › 文献综述 › 同行评审

摘要

FGFR1 is a key member of the fibroblast growth factor receptor family, mediating critical signaling pathways such as RAS-MAPK and PI3K-AKT. which are integral to regulating essential cellular processes, including proliferation, differentiation, and survival. Alterations in FGFR1 can lead to constitutive activation of signaling pathways that drive oncogenesis by promoting uncontrolled cell division, inhibiting apoptosis, and enhancing the metastatic potential of cancer cells. This article reviews the activation mechanisms and signaling pathways of FGFR1 and provides a detailed exposition of the types of FGFR1 aberration. Furthermore, we have compiled a comprehensive overview of current therapies targeting FGFR1 aberration in cancer, aiming to offer new perspectives for future cancer treatments by focusing on drugs that address specific FGFR1 alterations.

源语言英语
页(从-至)13131-13150
页数20
期刊Current Issues in Molecular Biology
卷46
期11
DOI
出版状态已出版 - 11月 2024

联合国可持续发展目标

此成果有助于实现下列可持续发展目标:

  1. 可持续发展目标 3 - 良好健康与福祉
    可持续发展目标 3 良好健康与福祉

学术指纹

探究 'Pharmacological and Biological Targeting of FGFR1 in Cancer' 的科研主题。它们共同构成独一无二的学术指纹。

引用此